Upload
others
View
3
Download
0
Embed Size (px)
Citation preview
29 May 2020SARS-Cov-2 ReportJosé Luis Pires
Confidential Hovione © 2020May 2020 2
SARS-Cov-2
➢ Confirmed cases by Country
➢ Deaths by Country
➢ Total confirmed Covid-19 cases and deaths per million people
➢ Portugal, Loures, Macau, New Jersey, Ireland - Cases by day and Total
➢ Reported infections per 1 million people for select countries with over 100 reported cases
➢ New cases vs 7-day average
➢ Cases Curve Simulator
➢ The latest coronavirus updates and developments impacting the global pharmaceutical supply
chain
Contents
Confidential Hovione © 2020May 2020 3
Coronavirus (SARS-CoV-2 / Covid-19) – Confirmed cases by countryNote: Selected Countries, sorted by # of cases
1,4731,6561,8051,8512,2452,9063,0763,8414,0086,7437,1737,6297,6438,41111,40211,71214,70215,58816,62016,62816,88724,84130,79631,59633,86035,72746,15257,849
84,10689,976
160,979165,829
182,450186,364
231,732237,906
270,508379,051
438,2381,721,750
0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000 1,600,000 1,800,000 2,000,000
SloveniaLithuania
IcelandEstoniaCroatiaGreece
ThailandHungary
LuxembourgFinland
AustraliaMalaysiaMoroccoNorway
KoreaDenmarkArgentina
PhilippinesJapan
AustriaIsrael
IrelandSwitzerland
PortugalSingapore
SwedenNetherlands
BelgiumChina
CanadaTurkey
IndiaGermany
FranceItaly
SpainUK
RussiaBrazil
US
Last Updated at 29 May 2020, 8:32 AM
by the Center for Systems Science and Engineering
at Johns Hopkins University
Sourc
e:
htt
ps:/
/gis
anddata
.maps.a
rcgis
.com
/apps/o
psdashboard
/in
dex.h
tml#
/bda759474
0fd
40
29
94
23
46
7b
48
e9
ecf6
17 April 202024 April 20201 May 20208 May 202015 May 202022 May 202029 May 2020
Confidential Hovione © 2020May 2020 4
Total confirmed Covid-19 cases per million people
Confidential Hovione © 2020May 2020 5
Coronavirus (SARS-CoV-2 / Covid-19) – Deaths by CountryNote: Selected Countries, sorted by # of cases
101,617
26,754
4,142
37,919
27,119
33,14228,665
8,4724,7134,461
6,9824,638
9,3885,9224,266
23 1,3691,9191,639284 668 881 921 508 568 269 236 202 115 103 313 110 517 57 175 102 66 10 68 1080
20,000
40,000
60,000
80,000
100,000
120,000
Source: https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6
Last Updated at 29 May 2020, 8:32 AM
by the Center for Systems Science and Engineering
at Johns Hopkins University
Confidential Hovione © 2020May 2020 6
Total confirmed Covid-19 deaths per million people
Confidential Hovione © 2020May 2020 7
Coronavirus (SARS-CoV-2 / COVID 19) – Portugal - Confirmed cases by day
2 2 2 3 4 8 9 9 2181934577686117
194143
235260
320
460
302
633
549
724
902
792
446
1035
808783
852
638
754
452
712699
815
1516
515
598
349
514
643
750
181
663
521
657
516
603
371
444
595
472
163
295
183
540
306
0
92
242
178
480533553
138175
98
234219187
264227226
173223228252
288271
152165219
285304350
0
200
400
600
800
1000
1200
1400
1600
2.m
ar
3.m
ar
4.m
ar
5.m
ar
6.m
ar
7.m
ar
8.m
ar
9.m
ar
10
.ma
r1
1.m
ar
12
.ma
r1
3.m
ar
14
.ma
r1
5.m
ar
16
.ma
r1
7.m
ar
18
.ma
r1
9.m
ar
20
.ma
r2
1.m
ar
22
.ma
r2
3.m
ar
24
.ma
r2
5.m
ar
26
.ma
r2
7.m
ar
28
.ma
r2
9.m
ar
30
.ma
r3
1.m
ar
1.a
pr
2.a
pr
3.a
pr
4.a
pr
5.a
pr
6.a
pr
7.a
pr
8.a
pr
9.a
pr
10
.ap
r1
1.a
pr
12
.ap
r1
3.a
pr
14
.ap
r1
5.a
pr
16
.ap
r1
7.a
pr
18
.ap
r1
9.a
pr
20
.ap
r2
1.a
pr
22
.ap
r2
3.a
pr
24
.ap
r2
5.a
pr
26
.ap
r2
7.a
pr
28
.ap
r2
9.a
pr
30
.ap
r1
.ma
y2
.ma
y3
.ma
y4
.ma
y5
.ma
y6
.ma
y7
.ma
y8
.ma
y9
.ma
y1
0.m
ay
11
.ma
y1
2.m
ay
13
.ma
y1
4.m
ay
15
.ma
y1
6.m
ay
17
.ma
y1
8.m
ay
19
.ma
y2
0.m
ay
21
.ma
y2
2.m
ay
23
.ma
y2
4.m
ay
25
.ma
y2
6.m
ay
27
.ma
y2
8.m
ay
29
.ma
y
Source: https://covid19.min-saude.pt/ponto-de-situacao-atual-em-portugal/
** - recalculated numbers
Confidential Hovione © 2020May 2020 8
Coronavirus (SARS-CoV-2 / COVID 19) – Portugal - Total cases by day
2 4 6 9 13 21 30 39 41 59 781121692453314486427851,0201,2801,6002,0602,362
2,9953,544
4,2685,170
5,9626,408
7,4438,251
9,0349,886
10,52411,278
11,73012,452
13,14113,956
15,47215,987
16,58516,93417,448
18,09118,84119,022
19,68520,206
20,86321,379
21,98222,35322,797
23,39223,86424,02724,32224,505
25,05625,35125,19025,28225,52425,70226,182
26,71527,26827,40627,58127,67927,91328,13228,31928,58328,81029,03629,20929,43229,66029,912
30,200
30,47130,62330,78831,00731,29231,596
31,946
0%
100%
50%50%
44%
62%
43%
30%
5%
44%
32%
44%
51%
45%
35%35%
43%
22%
30%25%
25%29%
15%
27%
18%20%21%
15%
7%
16%
11%9%9%6%7%
4%6%6%6%
11%
3%4%2%3%4%4%1%
3%3%3%2%3%2%2%3%2%1%1%1%2%1% 0%1%1%2%2%2%1%1%0%1%1%1%1%1%1%1%1%1%1%1%1%0%1%1%1%1%1%
0%
20%
40%
60%
80%
100%
120%
0
5000
10000
15000
20000
25000
30000
35000
# of cases % increase
Source: https://covid19.min-saude.pt/ponto-de-situacao-atual-em-portugal/
Confidential Hovione © 2020May 2020 9
Coronavirus (SARS-CoV-2 / COVID 19) – Portugal – Hospital: Stable vs ICU
0 0 0 0 9 132130384057
107107114139139
206
8989126
156169201203
276
191
354
418
486
571
627
726
10421058107510841099
11801211
117311791175117711871227
1200
1302128412531243
12081172
1146
10951068
10401005995
936980968
892855856
813818838
874842
815797805
709692680673657649628629
609608576
550536531513510529
0 0 0 0 0 0 0 0 0 0 0 0 0 10 9 18172020263541474861617189
136164
188230240245251267270271
245241226233228188
218208229222228224215213207204188186182176172169172154150144143134136135127120112112113103108112115108105101939284807872716666
0
200
400
600
800
1000
1200
1400
1.m
ar
2.m
ar
3.m
ar
4.m
ar
5.m
ar
6.m
ar
7.m
ar
8.m
ar
9.m
ar
10
.ma
r1
1.m
ar
12
.ma
r1
3.m
ar
14
.ma
r1
5.m
ar
16
.ma
r1
7.m
ar
18
.ma
r1
9.m
ar
20
.ma
r2
1.m
ar
22
.ma
r2
3.m
ar
24
.ma
r2
5.m
ar
26
.ma
r2
7.m
ar
28
.ma
r2
9.m
ar
30
.ma
r3
1.m
ar
1.a
pr
2.a
pr
3.a
pr
4.a
pr
5.a
pr
6.a
pr
7.a
pr
8.a
pr
9.a
pr
10
.ap
r1
1.a
pr
12
.ap
r1
3.a
pr
14
.ap
r1
5.a
pr
16
.ap
r1
7.a
pr
18
.ap
r1
9.a
pr
20
.ap
r2
1.a
pr
22
.ap
r2
3.a
pr
24
.ap
r2
5.a
pr
26
.ap
r2
7.a
pr
28
.ap
r2
9.a
pr
30
.ap
r1
.ma
y2
.ma
y3
.ma
y4
.ma
y5
.ma
y6
.ma
y7
.ma
y8
.ma
y9
.ma
y1
0.m
ay
11
.ma
y1
2.m
ay
13
.ma
y1
4.m
ay
15
.ma
y1
6.m
ay
17
.ma
y1
8.m
ay
19
.ma
y2
0.m
ay
21
.ma
y2
2.m
ay
23
.ma
y2
4.m
ay
25
.ma
y2
6.m
ay
27
.ma
y2
8.m
ay
29
.ma
y
Hospital Stable Hospital ICU
Source: https://covid19.min-saude.pt/ponto-de-situacao-atual-em-portugal/
Confidential Hovione © 2020May 2020 10
Coronavirus (SARS-CoV-2 / COVID 19) – Portugal – Deaths vs Recoveries
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 2 3 6 12142333436076100119140160187209246266295311345380409435470504535567599629657687714735762785820854880903928948973989100710231043106310741089110511141126113511441163117511841190120312181231124712631277
1289
130213161330134213561369
1383
0 0 0 0 0 0 0 0 0 0 0 1 1 1 2 3 3 3 3 5 5 5 142222434343434343436868757514018419620523326627727734738349351961061061091711461201122812771329135713891470151916471671168917121743
2076225824222499254925493013318231983328
3822
4636
6430643164526452
75907705
1754917822
180961834918637
18911
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
20000
1.m
ar
2.m
ar
3.m
ar
4.m
ar
5.m
ar
6.m
ar
7.m
ar
8.m
ar
9.m
ar
10
.ma
r1
1.m
ar
12
.ma
r1
3.m
ar
14
.ma
r1
5.m
ar
16
.ma
r1
7.m
ar
18
.ma
r1
9.m
ar
20
.ma
r2
1.m
ar
22
.ma
r2
3.m
ar
24
.ma
r2
5.m
ar
26
.ma
r2
7.m
ar
28
.ma
r2
9.m
ar
30
.ma
r3
1.m
ar
1.a
pr
2.a
pr
3.a
pr
4.a
pr
5.a
pr
6.a
pr
7.a
pr
8.a
pr
9.a
pr
10
.ap
r1
1.a
pr
12
.ap
r1
3.a
pr
14
.ap
r1
5.a
pr
16
.ap
r1
7.a
pr
18
.ap
r1
9.a
pr
20
.ap
r2
1.a
pr
22
.ap
r2
3.a
pr
24
.ap
r2
5.a
pr
26
.ap
r2
7.a
pr
28
.ap
r2
9.a
pr
30
.ap
r1
.ma
y2
.ma
y3
.ma
y4
.ma
y5
.ma
y6
.ma
y7
.ma
y8
.ma
y9
.ma
y1
0.m
ay
11
.ma
y1
2.m
ay
13
.ma
y1
4.m
ay
15
.ma
y1
6.m
ay
17
.ma
y1
8.m
ay
19
.ma
y2
0.m
ay
21
.ma
y2
2.m
ay
23
.ma
y2
4.m
ay
25
.ma
y2
6.m
ay
27
.ma
y2
8.m
ay
29
.ma
y
Total Confirmed Deaths Total Confirmed Recoveries
Source: https://covid19.min-saude.pt/ponto-de-situacao-atual-em-portugal/
Confidential Hovione © 2020May 2020 11
Coronavirus (SARS-CoV-2 / COVID 19) – Portugal – 28 May 2020
Confirmed Cases - Total Deaths - Total
Source: Expresso - https://expresso.pt/coronavirus/2020-05-15-Covid-19.-O-maior-aumento-de-novos-casos-dos-ultimos-sete-dias-o-surto-em-Portugal--em-graficos-e-mapas-
Confirmed Cases
Confidential Hovione © 2020May 2020 12
Coronavirus (SARS-CoV-2 / COVID 19) – Loures - Confirmed cases by day
4
0 0
29
78
12
17
8 89
4
13
4
2021
12
5 5
119
109
11
6
3
32
0
9
21
11
0 0
54
17
7 78
2
10
33
11
0
33
8
2
29
23
1715
13
8
30
14
22
37
56
31
17
9
35
31
40
48
0
10
20
30
40
50
60
24
.ma
r
25
.ma
r
26
.ma
r
27
.ma
r
28
.ma
r
29
.ma
r
30
.ma
r
31
.ma
r
1.a
pr
2.a
pr
3.a
pr
4.a
pr
5.a
pr
6.a
pr
7.a
pr
8.a
pr
9.a
pr
10
.ap
r
11
.ap
r
12
.ap
r
13
.ap
r
14
.ap
r
15
.ap
r
16
.ap
r
17
.ap
r
18
.ap
r
19
.ap
r
20
.ap
r
21
.ap
r
22
.ap
r
23
.ap
r
24
.ap
r
25
.ap
r
26
.ap
r
27
.ap
r
28
.ap
r
29
.ap
r
30
.ap
r
1.m
ay
2.m
ay
3.m
ay
4.m
ay
5.m
ay
6.m
ay
7.m
ay
8.m
ay
9.m
ay
10
.ma
y
11
.ma
y
12
.ma
y
13
.ma
y
14
.ma
y
15
.ma
y
16
.ma
y
17
.ma
y
18
.ma
y
19
.ma
y
20
.ma
y
21
.ma
y
22
.ma
y
23
.ma
y
24
.ma
y
25
.ma
y
26
.ma
y
27
.ma
y
28
.ma
y
29
.ma
y
Source: https://covid19.min-saude.pt/ponto-de-situacao-atual-em-portugal/
Confidential Hovione © 2020May 2020 13
Coronavirus (SARS-CoV-2 / COVID 19) – Loures - Total cases by day
24 28 28 2857 64 72 84
101109117126130131134138158
179191196201212221231240251257260292292301303304315315315
369386393400408410420
453464464497505507
536559
576591604612
642656
678
715
771802
819828
863894
934
982
17%
0%0%
104%
12%13%17%
20%
8%7%8%
3%1%2%3%
14%13%7%3%
3%5%4%5%4%5%
2%1%
12%
0%3%
1%0%4%
0%0%
17%
5%2%2%2%0%
2%
8%
2%0%
7%
2%0%
6%4%3%3%2%1%5%
2%3%5%
8%4%
2%1%4%4%4%5%
0%
20%
40%
60%
80%
100%
120%
0
200
400
600
800
1000
1200
24
.ma
r
25
.ma
r
26
.ma
r
27
.ma
r
28
.ma
r
29
.ma
r
30
.ma
r
31
.ma
r
1.a
pr
2.a
pr
3.a
pr
4.a
pr
5.a
pr
6.a
pr
7.a
pr
8.a
pr
9.a
pr
10
.ap
r
11
.ap
r
12
.ap
r
13
.ap
r
14
.ap
r
15
.ap
r
16
.ap
r
17
.ap
r
18
.ap
r
19
.ap
r
20
.ap
r
21
.ap
r
22
.ap
r
23
.ap
r
24
.ap
r
25
.ap
r
26
.ap
r
27
.ap
r
28
.ap
r
29
.ap
r
30
.ap
r
1.m
ay
2.m
ay
3.m
ay
4.m
ay
5.m
ay
6.m
ay
7.m
ay
8.m
ay
9.m
ay
10
.ma
y
11
.ma
y
12
.ma
y
13
.ma
y
14
.ma
y
15
.ma
y
16
.ma
y
17
.ma
y
18
.ma
y
19
.ma
y
20
.ma
y
21
.ma
y
22
.ma
y
23
.ma
y
24
.ma
y
25
.ma
y
26
.ma
y
27
.ma
y
28
.ma
y
29
.ma
y
# of cases % increase
Source: https://covid19.min-saude.pt/ponto-de-situacao-atual-em-portugal/
Confidential Hovione © 2020May 2020 14
Coronavirus (SARS-CoV-2 / COVID 19) – Lisbon - Confirmed cases by day
12
97
0
82
228
39
-128
4148
40
2027
18
55
1924
54
1623
15
41
16
3424
135
22
85
24
97
5
75
60
70
34
1831
71
0 012
4841
3224
112
54
202436
48
1924
56
28303139
31
5
24
483634
-150
-100
-50
0
50
100
150
200
250
24
.ma
r
25
.ma
r
26
.ma
r
27
.ma
r
28
.ma
r
29
.ma
r
30
.ma
r
31
.ma
r
1.a
pr
2.a
pr
3.a
pr
4.a
pr
5.a
pr
6.a
pr
7.a
pr
8.a
pr
9.a
pr
10
.ap
r
11
.ap
r
12
.ap
r
13
.ap
r
14
.ap
r
15
.ap
r
16
.ap
r
17
.ap
r
18
.ap
r
19
.ap
r
20
.ap
r
21
.ap
r
22
.ap
r
23
.ap
r
24
.ap
r
25
.ap
r
26
.ap
r
27
.ap
r
28
.ap
r
29
.ap
r
30
.ap
r
1.m
ay
2.m
ay
3.m
ay
4.m
ay
5.m
ay
6.m
ay
7.m
ay
8.m
ay
9.m
ay
10
.ma
y
11
.ma
y
12
.ma
y
13
.ma
y
14
.ma
y
15
.ma
y
16
.ma
y
17
.ma
y
18
.ma
y
19
.ma
y
20
.ma
y
21
.ma
y
22
.ma
y
23
.ma
y
24
.ma
y
25
.ma
y
26
.ma
y
27
.ma
y
28
.ma
y
29
.ma
y
Source: https://covid19.min-saude.pt/ponto-de-situacao-atual-em-portugal/
Confidential Hovione © 2020May 2020 15
Coronavirus (SARS-CoV-2 / COVID 19) – Lisbon - Total cases by day
175187
284284
366
594633
505546
594634654681699
754773797851867890905
9469629961,0201,0331,0381,060
1,1451,169
1,2661,271
1,3461,4061,4131,413
1,4471,4651,496
1,5671,5671,5671,5791,627
1,6681,7001,7241,7351,737
1,7911,8111,8351,871
1,9191,9381,9622,0182,046
2,076
2,1072,146
2,1772,1822,2062,254
2,290
2,324
7%
52%
0%
29%
62%
7%
-20%
8%9%7%
3%4%3%
8%
3%3%7%2%
3%
2%5%
2%4%2%1%0%
2%
8%
2%
8%
0%
6%4%
0%0%2%1%2%
5%
0%0%1%3%3%2%1%1%0%
3%1%1%2%3%
1%1%3%1%1%1%2%1%0%1%2%2%1%
-30%
-20%
-10%
0%
10%
20%
30%
40%
50%
60%
70%
0
500
1000
1500
2000
2500
24
.ma
r
25
.ma
r
26
.ma
r
27
.ma
r
28
.ma
r
29
.ma
r
30
.ma
r
31
.ma
r
1.a
pr
2.a
pr
3.a
pr
4.a
pr
5.a
pr
6.a
pr
7.a
pr
8.a
pr
9.a
pr
10
.ap
r
11
.ap
r
12
.ap
r
13
.ap
r
14
.ap
r
15
.ap
r
16
.ap
r
17
.ap
r
18
.ap
r
19
.ap
r
20
.ap
r
21
.ap
r
22
.ap
r
23
.ap
r
24
.ap
r
25
.ap
r
26
.ap
r
27
.ap
r
28
.ap
r
29
.ap
r
30
.ap
r
1.m
ay
2.m
ay
3.m
ay
4.m
ay
5.m
ay
6.m
ay
7.m
ay
8.m
ay
9.m
ay
10
.ma
y
11
.ma
y
12
.ma
y
13
.ma
y
14
.ma
y
15
.ma
y
16
.ma
y
17
.ma
y
18
.ma
y
19
.ma
y
20
.ma
y
21
.ma
y
22
.ma
y
23
.ma
y
24
.ma
y
25
.ma
y
26
.ma
y
27
.ma
y
28
.ma
y
29
.ma
y
# of cases % increase
Source: https://covid19.min-saude.pt/ponto-de-situacao-atual-em-portugal/
Confidential Hovione © 2020May 2020 16
Coronavirus (SARS-CoV-2 / COVID 19) – New Jersey - Confirmed cases by
day
1 0 3 2 5 4 8 6 2119298089160
315148
437587
930831
727
2474
1949
22992262
3347
2196
36493489
43724229
3382
3663
3361
3088
374836273563
3733
3219
4059
2625
4391
3150
2953
3881
35053581
3478
4124
2207
3327
3515
2150
2668
2408238825382527
3027
1525
2324
1297
17451819
1631
14471413
798817
1144120111841245
1705
974
1386
1073
1247
385
1050938
672
864
1187
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
5.m
ar
6.m
ar
7.m
ar
8.m
ar
9.m
ar
10
.ma
r
11
.ma
r
12
.ma
r
13
.ma
r
14
.ma
r
15
.ma
r
16
.ma
r
17
.ma
r
18
.ma
r
19
.ma
r
20
.ma
r
21
.ma
r
22
.ma
r
23
.ma
r
24
.ma
r
25
.ma
r
26
.ma
r
27
.ma
r
28
.ma
r
29
.ma
r
30
.ma
r
31
.ma
r
1.a
pr
2.a
pr
3.a
pr
4.a
pr
5.a
pr
6.a
pr
7.a
pr
8.a
pr
9.a
pr
10
.ap
r
11
.ap
r
12
.ap
r
13
.ap
r
14
.ap
r
15
.ap
r
16
.ap
r
17
.ap
r
18
.ap
r
19
.ap
r
20
.ap
r
21
.ap
r
22
.ap
r
23
.ap
r
24
.ap
r
25
.ap
r
26
.ap
r
27
.ap
r
28
.ap
r
29
.ap
r
30
.ap
r
1.m
ay
2.m
ay
3.m
ay
4.m
ay
5.m
ay
6.m
ay
7.m
ay
8.m
ay
9.m
ay
10
.ma
y
11
.ma
y
12
.ma
y
13
.ma
y
14
.ma
y
15
.ma
y
16
.ma
y
17
.ma
y
18
.ma
y
19
.ma
y
20
.ma
y
21
.ma
y
22
.ma
y
23
.ma
y
24
.ma
y
25
.ma
y
26
.ma
y
27
.ma
y
28
.ma
y
Source: https://www.nj.com/coronavirus/2020/03/see-the-spread-of-nj-coronavirus-in-charts-map-sunday-march-22-2020.html
Confidential Hovione © 2020May 2020 17
Coronavirus (SARS-CoV-2 / COVID 19) – New Jersey - Total cases by day
1 0 4 6 111523295069981782674277428901,3271,9142,8443,6754,4026,8768,825
11,12413,386
16,63618,69622,255
25,59029,895
34,12437,505
41,09044,416
47,43751,027
54,58858,151
61,85064,584
68,82471,030
75,31778,467
81,42085,301
88,80692,387
95,86599,989
102,196105,523
109,038111,188113,856
116,264118,652
121,190123,717
126,744128,269130,593131,890133,635135,454137,085138,532139,945140,743141,560142,704143,905145,089146,334148,039149,013150,399
151,472152,719153,104154,154155,092155,764156,628
157,815
50%
83%
36%
53%
26%
72%
38%
42%
82%
50%
60%
74%
20%
49%
44%
49%
29%
20%
56%
28%26%
20%
24%
12%
19%
15%17%
14%
10%10%8%7%8%7%7%6%
4%7%
3%6%
4%4%5%4%4%4%4%2%3%3%
2%2%2%2%2%2%2%1%2%1%1%1%1%1%1%1%1%1%1%1%1%1%1%1%1%1%0%1%1%0%1%1%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
0
20000
40000
60000
80000
100000
120000
140000
160000
1800005
.ma
r6
.ma
r7
.ma
r8
.ma
r9
.ma
r1
0.m
ar
11
.ma
r1
2.m
ar
13
.ma
r1
4.m
ar
15
.ma
r1
6.m
ar
17
.ma
r1
8.m
ar
19
.ma
r2
0.m
ar
21
.ma
r2
2.m
ar
23
.ma
r2
4.m
ar
25
.ma
r2
6.m
ar
27
.ma
r2
8.m
ar
29
.ma
r3
0.m
ar
31
.ma
r1
.ap
r2
.ap
r3
.ap
r4
.ap
r5
.ap
r6
.ap
r7
.ap
r8
.ap
r9
.ap
r1
0.a
pr
11
.ap
r1
2.a
pr
13
.ap
r1
4.a
pr
15
.ap
r1
6.a
pr
17
.ap
r1
8.a
pr
19
.ap
r2
0.a
pr
21
.ap
r2
2.a
pr
23
.ap
r2
4.a
pr
25
.ap
r2
6.a
pr
27
.ap
r2
8.a
pr
29
.ap
r3
0.a
pr
1.m
ay
2.m
ay
3.m
ay
4.m
ay
5.m
ay
6.m
ay
7.m
ay
8.m
ay
9.m
ay
10
.ma
y1
1.m
ay
12
.ma
y1
3.m
ay
14
.ma
y1
5.m
ay
16
.ma
y1
7.m
ay
18
.ma
y1
9.m
ay
20
.ma
y2
1.m
ay
22
.ma
y2
3.m
ay
24
.ma
y2
5.m
ay
26
.ma
y2
7.m
ay
28
.ma
y
# of cases % increase
Source: https://www.nj.com/coronavirus/2020/03/see-the-spread-of-nj-coronavirus-in-charts-map-sunday-march-22-2020.html
Confidential Hovione © 2020May 2020 18
Coronavirus (SARS-CoV-2 / COVID 19) – Macau - Confirmed cases by day
11
00
3
2
00000
1
0
2
00000000000000000000000000000000000000
111
22
11
2
5
22
3
22
11
2
00
111
00
1
0
0
1
2
3
4
5
6
Source: https://www.ssm.gov.mo/Portal/portal.aspx?lang=pt
51 days since last reported case
Confidential Hovione © 2020May 2020 19
Coronavirus (SARS-CoV-2 / COVID 19) – Macau - Total cases by day
1 12 2
5
7 7 7 7 7 78 8
10101010101010101010101010101010101010101010101010101010101010101010101010101011
1213
15
1718
19
21
26
28
3031
32
3738
39
41414142
43444444
45
0
5
10
15
20
25
30
35
40
45
50
23
.ja
n
25
.ja
n
27
.ja
n
29
.ja
n
31
.ja
n
2.f
ev
4.f
ev
6.f
ev
8.f
ev
10
.fe
v
12
.fe
v
14
.fe
v
16
.fe
v
18
.fe
v
20
.fe
v
22
.fe
v
24
.fe
v
26
.fe
v
28
.fe
v
1.m
ar
3.m
ar
5.m
ar
7.m
ar
9.m
ar
11
.ma
r
13
.ma
r
15
.ma
r
17
.ma
r
19
.ma
r
21
.ma
r
23
.ma
r
25
.ma
r
27
.ma
r
29
.ma
r
31
.ma
r
2.a
pr
4.a
pr
6.a
pr
8.a
pr
10
.ap
r
12
.ap
r
14
.ap
r
16
.ap
r
18
.ap
r
20
.ap
r
22
.ap
r
24
.ap
r
26
.ap
r
28
.ap
r
30
.ap
r
2.m
ay
4.m
ay
6.m
ay
8.m
ay
10
.ma
y
12
.ma
y
14
.ma
y
16
.ma
y
18
.ma
y
20
.ma
y
22
.ma
y
24
.ma
y
26
.ma
y
28
.ma
y
# of cases
Source: https://www.ssm.gov.mo/Portal/portal.aspx?lang=pt
51 days since last reported case
Confidential Hovione © 2020May 2020 20
Coronavirus (SARS-CoV-2 / COVID 19) – Ireland - Confirmed cases by day
1 0 0 1 4 7 5 1 2 31092720
394054
6974
191
126102
121
219204
235255
302294
200
295325
212
402424
331
390370
345365
500480
553
430
527548
657629
597630
445
401388
631
936
577
377
701
386
229
376359
221
343330
266
211
265
137156
219236
139107
159
426
129
9264
88
516476
115
765759
37
7346
Source: https://geohive.maps.arcgis.com/apps/opsdashboard/index.html#/29dc1fec79164c179d18d8e53df82e96
Confidential Hovione © 2020May 2020 21
Coronavirus (SARS-CoV-2 / COVID 19) – Ireland - Total cases by day
1 0 3 6 1318192124344370901291692232923665576837859061,1251,3291,5641,8192,1212,4152,6152,9103,2353,4473,849
4,3734,6044,9945,3645,7096,074
6,5747,054
8,9289,655
10,64711,479
12,54713,271
13,98014,758
15,25115,652
16,04016,671
17,60718,184
18,56119,262
19,64819,87720,25320,61220,83321,17621,50621,77221,98322,24822,38522,54122,76022,99623,13523,24223,40123,827
23,95624,04824,11224,20024,25124,315
24,391
24,50624,58224,63924,69824,73524,803
24,841
100%
117%
38%
6%
11%14%
42%
26%
63%
29%
43%31%
32%31%
25%
52%
23%
15%15%
24%
18%18%16%17%14%
8%11%11%
7%
12%14%
5%8%7%6%6%8%7%
27%
8%10%
8%9%6%5%6%
3%3%2%4%6%3%2%4%2%1%2%2%1%2%2%1%1%1%1%1%1%1%1%0%1%2%1%0%0%0%0%0%0%0%0%0%0%0%0%0%
0%
20%
40%
60%
80%
100%
120%
140%
0
5000
10000
15000
20000
25000
30000
29
.fe
v
2.m
ar
4.m
ar
6.m
ar
8.m
ar
10
.ma
r
12
.ma
r
14
.ma
r
16
.ma
r
18
.ma
r
20
.ma
r
22
.ma
r
24
.ma
r
26
.ma
r
28
.ma
r
30
.ma
r
1.a
pr
3.a
pr
5.a
pr
7.a
pr
9.a
pr
11
.ap
r
13
.ap
r
15
.ap
r
17
.ap
r
19
.ap
r
21
.ap
r
23
.ap
r
25
.ap
r
27
.ap
r
29
.ap
r
1.m
ay
3.m
ay
5.m
ay
7.m
ay
9.m
ay
11
.ma
y
13
.ma
y
15
.ma
y
17
.ma
y
19
.ma
y
21
.ma
y
23
.ma
y
25
.ma
y
27
.ma
y
# of cases % increase
Source: https://geohive.maps.arcgis.com/apps/opsdashboard/index.html#/29dc1fec79164c179d18d8e53df82e96
Confidential Hovione © 2020May 2020 22
Global infection snapshot: latest infection trends, declines from peak
infection levels and country GDP (size of bubble)
May 20, 2020 May 27, 2020
Confidential Hovione © 2020May 2020 23
New daily infections per 1 million people
May 20, 2020 May 27, 2020
Confidential Hovione © 2020May 2020 24
Infection and mortality for US states
Confidential Hovione © 2020May 2020 25
Daily deaths of
patients diagnosed
with coronavírus
(7-day average)
So
urc
e: h
ttp
s:/
/ww
w.f
t.co
m/c
on
ten
t/a
26fb
f7e
-48f8
-11
ea-a
eb3
-955
839
e06
441
Confidential Hovione © 2020May 2020 26
New
cases v
s
7-d
ay a
vera
ge
Country/CityTotal
cases
Total
deaths
New daily cases:
reported on 28 May
New daily cases:
7-day avg
New cases vs
7-day average
28 May 2020
C
o
l
New cases vs
7-day average
21 May 2020
C
o
l
u
New cases vs
7-day average
14 May 2020
C
o
l
u
New cases vs
7-day average
8 May 20202
C
o
l
u
New cases vs
7-day average
30 April 2020
C
o
l
u
New cases vs
7-day average
23 April 20202
C
o
l
u
New cases vs
7-day average
16 April 20202
C
o
l
u
New cases vs
7-day average
9 April 2020
C
o
l
u
New cases vs
7-day average
2 April 2020
Loures 934 40 31 Up Up Up Down Up Down Up Up Down
Lisbon 2,290 36 31 Up Down Up Up Down Up Up Down Up
New Jersey 157,815 1,187 906 Up Down Down Down Down Up Up Up Up
Cork 1,458
Argentina 14,702 508 600 631 Down Up Up Up Up Up Up Down Down
Australia 7,173 103 6 9 Down Down Down Up Down Down Down Down Down
Austria 16,628 668 18 34 Down Down Up Up Down Up Down Up Down
Belgium 57,849 9,388 137 230 Down Down Down Down Down Down Up Down Down
Brazil 438,238 26,754 16,324 17,085 Down Up Up Up Up Down Up Up Up
Canada 89,976 6,982 941 1,062 Down Down Down Down Down Down Up Up Up
China 84,106 4,638 3 6 Down Down Down Down Down Down Down Up Down
Croatia 2,245 102 0 1 Down Down Down Down Down Up Down Up Up
Denmark 11,712 568 52 52 Up Up Down Up Up Up Down Up Up
Estonia 1,851 66 6 7 Down Down Up Down Down Down Down Down Down
Finland 6,743 313 64 36 Up Down Down Up Up Down Down Up Down
France 186,364 28,665 148 220 Down Down Down Up Up Down Down Up Up
Germany 182,450 8,472 353 424 Down Up Up Up Down Down Down Up Up
Greece 2,906 175 11 8 Up Down Up Up Up Down Down Down Down
Hungary 3,841 517 23 25 Down Up Up Down Down Up Down Up Down
Iceland 1,805 10 1 0 Up Up Up Up Up Down Down Down Up
India 165,829 4,713 6,566 6,568 Down Up Up Up Up Up Down Down Down
Ireland 24,841 1,639 68 70 Down Down Down Down Down Up Up Up Down
Israel 16,887 284 28 16 Up Down Up Down Down Up Down Down Up
Italy 231,732 33,142 584 539 Up Down Down Down Down Up Down Down Down
Japan 16,620 881 32 37 Down Down Down Down Down Down Down Up Up
Korea 11,402 269 79 32 Up Down Up Down Down Down Down Down Down
Lithuania 1,656 68 8 10 Down Up Up Down Down Down Down Down Up
Luxembourg 4,008 110 6 4 Up Up Up Down Up Down Up Down Up
Malaysia 7,629 115 15 87 Down Down Down Down Up Down Down Down Down
Netherlands 46,152 5,922 190 189 Up Up Down Down Down Down Down Down Down
Norway 8,411 236 19 16 Up Down Down Up Up Up Up Down Down
Philippines 15,588 921 380 261 Up Up Up Up Up Down Up Down Down
Portugal 31,596 1,369 285 230 Up Up Down Up Down Down Down Down Up
Russia 379,051 4,142 8,371 8,785 Down Down Down Up Up Down Up Up Up
Singapore 33,860 23 533 502 Up Down Down Up Down Up Up Up Up
Slovenia 1,473 108 2 6 Down Up Up Down Up Down Up Up Down
Spain 237,906 27,119 510 655 Down Down Down Down Down Down Up Down Down
Sweden 35,727 4,266 648 509 Up Up Up Up Up Up Down Up Up
Switzerland 30,796 1,919 15 17 Down Up Down Down Down Down Up Down Down
Thailand 3,076 57 11 4 Up Up Down Down Down Down Down Down Down
Turkey 160,979 4,461 1,035 1,030 Up Down Up Up Up Down Down Up Up
UK 270,508 37,919 2,013 2,707 Down Down Down Up Down Down Down Up Up
US 1,721,750 101,617 24,886 22,431 Up Up Down Down Down Down Down Up Up
Confidential Hovione © 2020May 2020 27
• This COVID-19 Active Cases Curve Simulator has been developed by the IQVIA Data Science and Advanced Analytics team as a tool to
help stakeholders make decisions based on the level and trajectory of active cases in their country, region or state
• The core of the model is the Susceptible-Exposed-Infectious-Removed epidemiology model, and inputs are from publicly available
sources updated daily
• The simulator focuses on “total active cases” as a metric that speaks to the overall impact COVID-19 is having, not just limited to
hospitalizations or deaths (where other models are focused, e.g. IHME). We believe the active cases curve will be used by public health
officials – along with other considerations, such as availability of testing – to guide their decision- making on modifying stay-at-home rules
• Active cases are those confirmed diagnosed cases, excluded those that have recovered or died.
• The simulation shows the number of active cases (per population), shape of increase of the curve, timing of the apex of the curve and the
shape and timing of the decline from the apex.
• Scenarios are labelled as “normal”, “optimistic” and “pessimistic” based on the following
• “Normal” scenario means the model parameters are derived to fit most closely to the actual reported public data
• “Optimistic” scenario is the lower bound, assuming people closely follow nonpharmaceutical interventions (NPIs), and reference what was
achieved in other countries with similar characteristics
• “Pessimistic” scenario is the upper bound, assuming people do not closely follow NPIs and time from exposure to diagnosis takes longer
than reported in the literature
Cases Curve Simulator
Source: IQVIA, April 2020
Confidential Hovione © 2020May 2020 28
Simulation band of active cases in next 150 days in U.S.
Source: IQVIA, May27, 2020
Projected total
confirmed cases
Projected total
confirmed cases
per 100k
population
Estimated
Peak time
Optimistic
Scenario1.8M 558.3 5/27/2020
Normal
Scenario2.9M 889.3 5/30/2020
Pessimistic
Scenario3.5M 1072.7 6/5/2020
Confidential Hovione © 2020May 2020 29
Simulation of active cases per 100k population in next 150 days in US
Source: IQVIA, May27, 2020
Confidential Hovione © 2020May 2020 30
Simulation band of active cases in next 150 days in Italy
Projected Total
Confirmed
Cases
Projected total
confirmed
cases per 100K
population
Estimated peak
time
Optimistic
Scenario233.2K 388.6 4/19/2020
Normal
Scenario243.8K 406.3 4/19/2020
Pessimistic
Scenario270.2K 450.3 4/19/2020
Source: IQVIA, May27, 2020
Confidential Hovione © 2020May 2020 31
Simulation band of active cases in next 150 days in Germany
Projected
Total
Confirmed
Cases
Projected Total
Confirmed
Cases per 100k
Population
Estimated
Peak Time
Optimistic
Scenario185.2K 222.7 04/06/2020
Normal
Scenario186.8K 224.7 04/06/2020
Pessimistic
Scenario189.0K 227.3 04/06/2020
Source: IQVIA, May27, 2020
Confidential Hovione © 2020May 2020 32
Simulation band of severe active cases in next 150 days in UK
Projected
Total
Severe
Confirmed
Cases
Projected
Total Severe
Confirmed
Cases per
100kPopulation
Estimated
Peak Time
Optimistic
Scenario285.6K 429.9 05/07/2020
Normal
Scenario295.8K 445.2 05/07/2020
Pessimistic
Scenario311.5K 468.9 05/07/2020
Source: IQVIA, May27, 2020
Confidential Hovione © 2020May 2020 33
Simulation band of active cases in next 150 days in Spain
Projected
Total
Confirmed
Cases
Projected Total
Confirmed
Cases per 100k
Population
Estimated
Peak Time
Optimistic
Scenario240.1K 516.3 04/17/2020
Normal
Scenario247.7K 532.7 04/17/2020
Pessimistic
Scenario261.7K 562.7 04/17/2020
Source: IQVIA, May27, 2020
Confidential Hovione © 2020May 2020 34
• 28 May
• Oxford Biomedica penned a one-year clinical and commercial supply deal with AstraZeneca to scale up manufacturing for the COVID-19 vaccine candidate AZD1222.
• Roche announced a new partnership with Gilead as the drugmakers started a phase III study testing the Swiss drugmaker's immunology med Actemra/RoActemra alongside Gilead's antiviral
remdesivir to treat COVID-19. Roche plans to begin enrollment in June, with a target of 450 patients globally.
• Moderna expanded a 2016 deal with Swiss pharmaceutical ingredient maker CordenPharma on Thursday to secure large quantities of lipids for its experimental COVID-19 vaccine mRNA-
1273. The deal grants access to two additional CordenPharma manufacturing sites in France and the U.S. as Moderna looks to boost its vaccine stores in anticipation of success in the clinic.
• GlaxoSmithKline (GSK) has announced it will manufacture one billion doses of its pandemic adjuvant by 2020.
Although GSK is not producing its own Covid-19 vaccine, it is supporting on a non-profit basis other companies who are with its pandemic adjuvant. During previous flu pandemic, this part of
the vaccine, which boosts the immune response, was shown to reduce the amount of protein needed per dose, therefore allowing more doses to be produced.
• 27 May
• The World Health Organization is putting a stop to global studies into the effectiveness of hydroxychloroquine after repeated safety concerns. The decision came following a study published
in The Lancet that showed patients who took hydroxychloroquine were at higher risk of death and heart problems than those who did not.
• 26 May
• Gilead's remdesivir has shown promising results, but some limits, too. Detailed data published in the New England Journal of Medicine showed that on average, hospitalized patients
receiving remdesivir recovered a median of four days faster than patients on placebo, with mortality in the remdesivir group at 7.1% compared to the placebo group's 11.9%. But the data also
suggest the drug offers more benefits to patients on oxygen therapy than to the critically ill on mechanical ventilators.
• The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted early access to remdesivir in its medicines scheme for conditions with a high unmet medical need.
• 25 May
• Like all industries, the pharma industry has been disrupted by the Covid-19 pandemic. The generics industry has been impacted particularly by supply chain problems and huge surges in
demand for existing medicines.
• Accord’s head of scientific affairs Dr Anthony Grosso explains how the industry has worked to overcome these challenges and respond to the needs of patients, as well as become more
prepared for future healthcare emergencies.
• 24 May
• Experts across world continue to highlight the need to reopen economies to limit the economic upheaval caused by the Covid-19 pandemic.
• However, some believe that unless testing capabilities are ramped up, reopening the economy may result in an upsurge in infection rate.
The latest coronavirus updates and developments impacting the global
pharmaceutical supply chain…
Confidential Hovione © 2020May 2020 35
Pandemics – Number of Deaths
Source: Expresso - https://expresso.pt/coronavirus/2020-05-15-Covid-19.-O-maior-aumento-de-novos-casos-dos-ultimos-sete-dias-o-surto-em-Portugal--em-graficos-e-mapas-
Confidential Hovione © 2020May 2020 36
• 22 May
• Beximco Pharma launches first generic remdesivir for Covid-19, under the brand name Bemsivir.
• 21 May
• AstraZeneca has secured over $1 billion from the HHS' BARDA for the development and supply of the Oxford University vaccine it has partnered on.
• Moderna is currently the leader in the mRNA vaccine space, but Evercore ISI analyst Umer Raffat is raising doubts about the strength of the preliminary phase 1 data the biotech recently
posted.
• AstraZeneca has previously also invested in Moderna.
• The unemployment rate in the US currently stands at 14.7% but for people aged between 20 and 24, the rate increases to 25.7%, according to statistics provided by the BLS.
• 20 May
• People with Type 1 diabetes are three and a half times more likely to die than non-diabetics who catch COVID-19 while Type 2 patients are twice as likely to die than non-diabetics, NHS
England has found.
• 19 May
• Gilead Sciences has pledged to donate its current supply of 1.5 million doses of remdesivir, of which 607,000 vials are being allocated to the U.S. government. Now, the biotech is increasing
its U.S. donation to about 940,000 doses by June.
• The Trump administration has signed a $354 million four-year deal with with a new Virginia company called Phlow to produce generic drugs and APIs needed to treat COVID-19 in an effort
to bring pharma manufacturing back to the U.S.
• Meanwhile, Cipla, which is one of four drugmakers with nonexclusive remdesivir licensing deals, is also looking at combo treatment options for COVID-19, including teaming Fujifilm's flu drug
Avigan (favipiravir) with the Gilead med.
• 18 May
• Moderna shares leapt as the company unveiled early phase 1 data showing its vaccine candidate, mRNA-1273, elicited neutralizing antibodies in eight trial participants available for analysis.
Based on the data, The company said its own phase 2 trial will be amended to study two dose levels, 50 µg and 100 µg.
• On the heels of unveiling early results for its mRNA vaccine, Moderna plans to raise $1.34 billion through a stock sale to help produce the shot if it crosses the regulatory finish line.
• Moncef Slaoui, the newly appointed U.S. coronavirus czar, will divest his $10 million in Moderna stock options, which shot up in value Monday after the company unveiled promising early
data.
• 17 May
• The EU could grant Gilead's remdesivir an conditional nod in the "coming days," EMA head Guido Rasi said on Monday at a hearing at the EU Parliament in Brussels.
The latest coronavirus updates and developments impacting the global
pharmaceutical supply chain… (cont.)
Confidential Hovione © 2020May 2020 37
• 14 May
• After a fast-tracked approval, Japan has already started distributing Gilead Sciences' remdesivir to hospitals. The drug is being used for patients in intensive care or on ventilators.
• The United Nations’s International Labour Organization predicts 1.6bn informal economy workers could suffer “massive damage” to their livelihoods.
• In the second quarter of 2020, Covid-19 may cost the equivalent of 305 million full-time jobs.
• Current G7 jobless totals vary widely, from 30 million in the United States to 1.76 million in Japan.
• McKinsey believe that Europe’s CEOs will have to draw on the region’s spirit of innovation to recover post Covid-19.
• 13 May
• The US Food and Drug Administration (FDA) has granted fast track designation to Moderna’s Covid-19 vaccine candidate, mRNA-1273.
• Even if Moderna succeeds with its unproven vaccine platform, the biotech won't be able to make enough doses for the entire world, CEO Stephane Bancel said.
• After Gilead inked a series of licensing deals for remdesivir, Public Citizen argued the drug should be in the public domain.
• 12 May
• Gilead inked licensing deals with generic drugmakers Cipla, Ferozsons Laboratories, Hetero Labs, Jubilant Lifesciences and Mylan allowing those companies to manufacture and distribute
remdesivir in 127 countries, royalty-free.
• The European Medicines Agency expanded its compassionate use guidelines for Gilead's remdesivir. Originally, the drug was recommended for patients requiring mechanical ventilation. It's
now recommended for certain hospitalized patients.
• 11 May
• Physicians and hospitals have already expressed frustrations about the difficulty obtaining Gilead Sciences' remdesivir. Now, an HHS distribution plan shows that only 607,000 vials of the
emergency use drug will be made available to U.S. patients over the next six weeks, out of a total donation of about 1.5 million
• 9 May
• Gilead Sciences may have been the target of Iranian hackers using fake email login pages to access confidential data, Reuters reported. In one case, a fake login page was sent to a legal
and corporate affairs executive in April. Reuters couldn't confirm whether the attack was successful.
• Speaking of Gilead, the National Institutes of Health will pair the drugmaker's COVID-19 antiviral remdesivir with Eli Lilly's rheumatoid arthritis drug Olumiant in a new study in U.S.
hospitalized patients. The trial will eventually enroll 1,000 patients across 100 sites, the NIH said.
• After the FDA's emergency use authorization, Gilead donated its entire stockpile of remdesivir to the government for further distribution. But the drug hasn't reached those most in need,
according to Axios. "Some went to the wrong places, some went to the right places," one senior Trump administration official said. "We don't know who gave the order. And no one is claiming
responsibility."
The latest coronavirus updates and developments impacting the global
pharmaceutical supply chain… (cont.)
Confidential Hovione © 2020May 2020 38
• 8 May
• Hydroxychloroquine has failed an observational study in New York. According to a paper published in The New England Journal of Medicine, researchers found no significant difference
between hydroxychloroquine and standard care in terms of patients' need for ventilation or death rate.
• After the FDA's emergency use authoriziation, Gilead has donated its entire stockpile of remdesivir to the government for further distribution.
• FDA authorises Moderna to conduct Phase II trial of Covid-19 vaccine
• 7 May
• Gilead Sciences' remdesivir won approval in Japan as Veklury. It's the first full global nod for the COVID-19 treatment following the U.S. emergency use authorization last week. Authorities in
Japan approved the drug under an "exceptional approval" regulatory pathway.
• Gilead spent about $50 million on remdesivir manufacturing scale-up and clinical trial costs during the first quarter.
• Moderna is planning an "imminent" start to a 600-participant phase 2 trial of its mRNA vaccine candidate, mRNA-1273, after the FDA cleared its trial protocol. The company's goal is to
initiate a phase 3 study "early this summer" and win approval as soon as 2021.
• 6 May
• Gilead Sciences says it’s in licensing talks with the “world’s leading chemical and pharmaceutical manufacturing companies” about their ability to produce remdesivir for countries in Europe,
Asia and beyond until at least 2022.
• Scientists have identified a new strain of the coronavirus that appears to be more contagious than the early versions in the pandemic, according to a new study led by scientists at Los
Alamos National Laboratory.
• 5 May
• A drugmaker in Bangladesh, Beximco, plans to start making Gilead's newly FDA-authorized remdesivir for $59 to $71 per vial, Reuters reports. The company is planning to produce the drug
for domestic use, at least initially. It isn't clear whether Beximco had a licensing deal to manufacture the product.
• 4 May
• How much should Gilead Sciences charge for remdesivir? Up to $4,460 per patient, according to the Institute for Clinical and Economic Review. But even at $1,000 per patient—less than a
quarter of ICER's pitched price—Gilead could theoretically rake in $1 billion in sales, as it looks to build a supply capable of treating 1 million patients by the end of the year.
• 2 May
• Moderna Therapeutics has tapped Lonza to help manufacture the biotech's mRNA vaccine candidate, dubbed mRNA-1273.
The latest coronavirus updates and developments impacting the global
pharmaceutical supply chain… (cont.)
Confidential Hovione © 2020May 2020 39
• 30 April
• Economic Outlook: Covid-19 puts 1.6 billion jobs at risk – Q1 company earnings ‘most watched in history’ say Goldman Sachs.
• GDP of majority of the economies to be below pre-Covid-19 levels for two to three years.
• Gilead’s remdesivir meets endpoint in NIAID study.
• GlobalData Epidemiologist Report – Covid-19 now affects 187 countries – over 1 million cases in US
• 29 April
• The US economy has contracted at an annual rate of 4.8%, the steepest slump since the 2008 recession. This brings the longest ever period of economic expansion in the US to an end.
• It is predicted that gross domestic product (GDP) could drop by 30% in the next quarter, as many “stay-at-home” measures were only implemented at the end of this quarter, with a sharp
rise in unemployment also anticipated.
• 28 April
• On the back of disappointing results for Sanofi and Regeneron’s IL-6 inhibitor, Kevzara yesterday, a research team from the Assistance Publique-Hôpitaux de Paris announced that an open-
label, randomized, controlled study of Roche’s Actemra in 129 moderate to severe COVID-19 patients with pneumonia was successful.
• UK Approves Clinical Trial Of Plasma Therapy for COVID-19.
• Covid-19’s impact on drug contract manufacture in Italy. GlobalData’s Contract Service Provider database shows there are 148 CMOs with Italian facilities
• 27 April
• Another high profile drug being repurposed for COVID-19 treatment faced a major setback this morning. Sanofi and Regeneron’s IL-6 inhibitor, Kevzara showed no benefit in “severe”
COVID-19 patients requiring oxygen therapy.
• China has granted approval to assess a third coronavirus vaccine candidate against COVID-19 in the second phase of clinical trials.
• Vaccine major Serum Institute of India on Sunday said it plans to start production of the COVID-19 vaccine developed by Oxford University in the next two to three weeks and hopes to bring
it to the market by October if the human clinical trials are successful.
• France, Italy and Spain announce easing of lockdown measures.
• 24 April
• On April 23rd, news broke of a potential failure of Gilead's COVID-19 candidate, remdesivir, to improve mortality in hospitalized adult patients with severe COVID-19 from a trial in China.
However, any data reported here must be approached with caution, as the full results of the study have not yet been made available, and what has been released is from a trial which was
terminated due to difficulties in recruitment.
The latest coronavirus updates and developments impacting the global
pharmaceutical supply chain… (cont.)
Confidential Hovione © 2020May 2020 40
• 23 April
• Gilead’s remdesivir has failed to show benefit in a clinical trial conducted to treat Covid-19 patients in China, according to data the WHO accidentally posted on its website.
• Preliminary reports from epidemiological studies suggest that countries with universal BCG vaccination programs have been impacted less by Covid-19
• 22 April
• The Covid-19 pandemic is expected to widen the gap between the poor and rich creating massive inequality and high unemployment rates.
• The world is on track for a recession of “unprecedented depth in the post-war period”, ratings agency Fitch says with world gross domestic product to tumble by 3.9% in 2020.
• 21 April
• Pharma CEOs are asking that governments pour out billions of dollars in advance for the development and production of potential COVID-19 drugs.
• Following other companies such as Pfizer and Novo Nordisk, Merck & Co. is now also expanding its patient assistance program, allowing eligible patients to get its medicines at no cost.
• To ease shortages of drugs for COVID-19 patients who are on ventilators, the FDA is now allowing small compound pharmacies to temporarily fill the supply gap.
• 20 April
• Researchers at the NIH and Gilead have published results from an animal trial of remdesivir, involving 12 rhesus macaques, showing that early antivrial treatment reduced COVID-19
symptoms and lung damage.
• Though the COVID-19 pandemic has upended the public markets—and thrown a wrench into what was expected to be a stellar IPO season—the biotech industry could be that particular
cloud’s silver lining, as investors look toward additional windows and opportunities later this year.
• A congressman is calling on the SEC to investigate last week’s leak of remdesivir data, along with its impact on the stock market and a 15% boost in Gilead’s share price. Though the
antiviral is not supposed to be a moneymaker for the Big Pharma, news following its development has added billions to Gilead’s market cap.
• The FDA has granted emergency use authorizations to four antibody diagnostics—also known as serology tests—that promise to help identify individuals who have been exposed to the
novel coronavirus.
• 19 April
• Meanwhile, in the U.S., the FDA has stepped up seizures of prescription drugs being sent to American customers from Canada and other countries, where they are sold at cheaper prices,
according to Kaiser Health News.
• 18 April
• In the European region, it’s notable that the number of cases are increasing in Belgium with a total of 34,809 cases, placing the country in rank just after the UK, though the gap between the
two countries is large.
The latest coronavirus updates and developments impacting the global
pharmaceutical supply chain… (cont.)
Confidential Hovione © 2020May 2020 41
• 17 April
• BARDA supports Moderna’s vaccine.
• Promise of Gilead’s remdesivir made clear.
• Nasal spray vaccine on the horizon.
• 16 April
• Millions of doses of hydroxychloroquine donated to the U.S. by Bayer have come under scrutiny after the quality of the drug's Indian and Pakistani active pharmaceutical ingredients and
finished doses may have never passed FDA inspections, sources told Reuters. Bayer has donated 3 million tablets of the drug, called Resochin, to the U.S. national stockpile for treatment of
COVID-19.
• Despite the fact that Fujifilm's Avigan hasn't been proven as an effective COVID-19 treatment, Japan and China are providing the drug to other countries, the Wall Street Journal reports.
• 15 April
• India is hoping to rapidly expand its production of global active pharmaceutical ingredients to compete with China's dominance in the market amid COVID-19 lockdowns, Bloomberg reported.
The country is one of the largest providers of generic drugs to the U.S.
• Gilead Sciences is among the companies with promising COVID-19 drugs and the company has now applied for a trademark for potential remdesivir packaging. But at press time, the
company's shares were down on word that a second China trial had been stopped for lack of enrollment.
• As the White House's Tuesday press briefing, President Donald Trump said the U.S. is halting funding to the World Health Organization. Bill Gates and others blasted the move.
• 14 April
• China's National Medical Products Administration has greenlit two inactivated COVID-19 vaccines to start human testings.
• Sanofi and GSK, two of the world’s biggest vaccine makers, are joining forces to develop a recombinant DNA vaccine, aiming to enter clinical testing in the second half of 2020.
• 13 April
• Rutgers University has received the FDA’s first emergency authorization for a COVID-19 diagnostic that uses easy-to-collect saliva samples instead of the more difficult deep nose swabs.
• Gilead provided results from 53 severe COVID-19 patients treated with remdesivir on a compassionate use basis in a paper published in The New England Journal of Medicine. During a
median follow-up of 18 days, 36 patients (68%) had a clinical improvement, and the mortality rate was 18% among patients receiving invasive ventilation. Jefferies analysts argue the data
"suggest remdesivir may work and is generally safe."
• 10 April
• Gilead's promising COVID-19 drug candidate remdesivir could be made at $9 per treatment, while the estimated manufacturing cost for generic hydroxychloroquine stands as little as $1 per
course, a study published in the Journal of Virus Eradication found.
The latest coronavirus updates and developments impacting the global
pharmaceutical supply chain… (cont.)
Confidential Hovione © 2020May 2020 42
• 9 April
• Pfizer says a Phase 2 investigator-initiated study for the use of tofacitinib, a JAK inhibitor, in patients with SARS-CoV-2 interstitial pneumonia is about to start in Italy.
• Mylan says its expedited manufacturing of hydroxychloroquine has resulted in stocks being available ahead of schedule.
• Analysts at Morningstar say the coronavirus pandemic will affect Big Pharma and Big Biotech companies in two major ways: an economic slowdown, likely causing a 4.6% hit to 2020 global
GDP (implying a 1.4% decline in 2020), and a disruption in the use of drugs, vaccines, and consumer healthcare products. “However, the highly inelastic demand for most drugs should
largely offset any recessionary impact,” they add.
• 8 April
• The European Commission publishes its guidelines on the optimal and rational supply of medicines to avoid shortages during the COVID-19 outbreak.
• US Food and Drug Administration commissioner Stephen Hahn says that since the agency issued its policy to allow developers of serological tests to identify patients that have developed an
immune response to market them without FDA review, over 70 tests are available for use.
• 7 April
• Bristol Myers Squibb announces an expansion of its patient support programs to help unemployed US patients who have lost their health insurance due to the COVID-19 pandemic.
• 6 April
• India lifts export restrictions on 12 APIs and their formulations including antibiotics, vitamins and hormones with immediate effect, according to a Directorate General of Foreign Trade
notification. Paracetamol and hydroxychloroquine are notable omissions from the list.
• Thermo Fisher Scientific says that due to the COVID-19 pandemic, it is withdrawing its 2020 annual financial guidance, which was provided on January 30. “As the pandemic spread from
China to countries worldwide, the company saw a significant reduction in customer activity by late March.
• 4 April
• In an open letter, Gilead CEO Daniel O’Day says the biotech company has managed to reduce the end-to-end manufacturing timeline for its antiviral remdesivir – which has shown potential
to treat patients with severe COVID-19 -- from one year to around six months.
• India’s Directorate General of Foreign Trade announces an immediate blanket ban on exports of hydroxychloroquine “without any exceptions.”
The latest coronavirus updates and developments impacting the global
pharmaceutical supply chain… (cont.)
Confidential Hovione © 2020May 2020 43
• 3 April
• Generics industry association Medicines for Europe supports a call by the European University Hospital Alliance for European coordinated efforts to prevent shortages of ICU medicines –
which include sedatives, muscle relaxants, antibiotics and anaesthetics -- amid rising demand.
• Novartis says it plans to start a clinical trial of its JAK inhibitor, Jakavi (ruxolitinib), in patients with COVID-19 associated cytokine storm, a form of severe immune overreaction that can result
from coronavirus infection.
• 2 April
• Roche Canada announces its COVID-19 Innovation Challenge, a competition to bring forward innovative ideas to fight the pandemic.
• Amgen and Adaptive Biotechnologies announce a partnership to develop neutralizing antibodies targeting SARS-CoV-2 to potentially prevent or treat COVID-19.
• The US Food and Drug Administration approves Celularity’s Investigational New Drug application for its CYNK-001 cell therapy in adults with COVID-19.
• The European Medicines Agency says chloroquine and hydroxychloroquine, currently authorised for malaria and certain autoimmune diseases but being investigated for their potential to
treat COVID-19, should only be used in clinical trials or emergency use programmes.
• 1 April
• AbbVie is donating USD35 million to support COVID-19 relief efforts.
• Gilead announces that it has started two Phase 3 studies of its investigational antiviral treatment, remdesivir, in patients with moderate to severe COVID-19 in the UK.
• The US Food and Drug Administration says it has launched a program to speed up the development of treatments for COVID-19.
• 31 March
• The US government is in discussions with India over a possible relaxing of restrictions on API exports from India imposed at the start of March.
• China is stepping up its efforts to produce and ship APIs with a focus on meeting international demand, particularly for those showing potential to treat the COVID-19 disease
• 30 March
• In a letter to customers, CordenPharma says it has halted routine manufacturing at its Bergamo facility in northern Italy for one week from 26 March to 1 April due to supply chain interruption
and staffing issues.
• Novartis announces that its generics unit Sandoz has started to ship 30 million doses of hydroxychloroquine to the US Department of Health and Human Services for use in clinical studies to
test its effectiveness in people who have tested positive for COVID-19.
The latest coronavirus updates and developments impacting the global
pharmaceutical supply chain… (cont.)
Confidential Hovione © 2020May 2020 44
• 27 March
• Sanofi and Translate Bio are collaborating to develop a novel mRNA vaccine candidate against COVID-19, extending an existing 2018 agreement between the two firms on mRNA vaccines
for infectious diseases.
• Wuxi Biologics says more than 98% of its staff are now back at work after the country’s recent lockdown. The Chinese CDMO says it has received “a surge of requests” in March for new
projects, predominantly from clients outside of China.
• 26 March
• The proposed merger Mylan and Pfizer’s generics division, Upjohn, is postponed until the second half of 2020 due to the COVID-19 pandemic. Mylan’s EGM has been pushed back two
months to 30 June.
• A consortium of fifteen biopharma companies have agreed to share their proprietary libraries of drugs that already have promising safety and activity data with the COVID-19 Therapeutics
Accelerator launched by the Gates Foundation, Wellcome, and Mastercard to quickly screen them for potential against COVID-19. The firms include BD, Boehringer Ingelheim, bioMerieux,
Eisai, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck & Co., Merck KGaA, Novartis, Pfizer and Sanofi.
• Mylan waives its right to a 180-day marketing exclusivity period in the US to distribute its generic version of antiretroviral Kaletra (lopinavir/ritonavir) to help increase the available supply of
the product should it prove effective in treating patients with COVID-19.
• 25 March
• Medicines for Europe says export restrictions (including some within the EU) on drug and ingredients manufacturers is undermining European production. The generics industry body says its
mid-February request for effective coordination between manufacturers and authorities to manage the crisis has not been fully realized. “We deeply regret that this process is not yet fully
operational at EU or at national level except in Italy,” it says.
• Vir Biotechnology announces that it has identified multiple human monoclonal antibody (mAb) development candidates that neutralize SARS-CoV-2, the virus responsible for COVID-19. The
firm expects human trials to begin within 3-5 months.
• Suven Pharmaceuticals warns customers it cannot export finished products due to a shortage of raw materials following India’s recent lockdown to fight COVID-19.Suven Pharmaceuticals
warns customers it cannot export finished products due to a shortage of raw materials following India’s recent lockdown to fight COVID-19.
• CDMO Catalent reaffirms it has not identified any significant risk or delay that may have a substantial effect on delivery of products or clinical trial supplies.
The latest coronavirus updates and developments impacting the global
pharmaceutical supply chain… (cont.)
Confidential Hovione © 2020May 2020 45
• 24 March
• Switzerland-headquartered CDMO Siegfried is supplying disinfectant in the Swiss and German regions where it operates production sites. It says it will not supply private or commercial
organizations.
• In a letter to customers, CDMO CordenPharma says it has instructed all employees to cancel all business travel and face-to-face meetings until the end of April. It says all its manufacturing
facilities in Italy, Germany, France, Switzerland and the US are fully operational.
• CMO Argonaut Manufacturing Services says it is ready to provide services for pre-clinical to Phase III manufacturing of vaccines and therapeutics, including those for firms working toward a
COVID-19 vaccine or therapeutic under accelerated timelines.
• 23 March
• The International Generic and Biosimilar medicines Association, representing generic and biosimilar manufacturers, urges governments to reopen air freight routes to ensure access to
medicines during the COVID-19 pandemic.
• Roche’s Genentech in collaboration with the Biomedical Advanced Research and Development Authority says the FDA has approved a Phase III clinical trial of its arthritis drug Actemra
(tocilizumab) to treat hospitalized adult patients with severe COVID-19 pneumonia.
• Eli Lilly becomes the first Big Pharma company to announce its clinical trials are being adversely affected by coronavirus. The firm says it is delaying most new study starts and pausing
enrollment of new patients or volunteers “to ease the burden on participating healthcare facilities.”
• 22 March
• Gilead says it is no longer accepting requests for emergency access to its antiviral remdesivir due to an “exponential increase” in such requests and “overwhelming demand.”
• 21 March
• The Indian government approves a USD1.8 billion scheme to boost production of APIs and medical devices. The plan involves development of three mega API drug parks in partnership with
states and financial incentives to manufacturers of 53 identified critical APIs on incremental sales for the next six years.
• In a filing to the Bombay Stock Exchange, Ipca Laboratories says the US FDA has lifted an import alert on its hydroxychloroquine sulphate and chloroquine phosphate APls and
hydroxychloroquine sulphate tablets due to the shortage implications of coronavirus.
• Bristol Myers Squibb says it has now implemented a mandatory work from home policy for its workforce. “All employees, contingent workers and contractors who can do their jobs from home
must do so,” it says.
The latest coronavirus updates and developments impacting the global
pharmaceutical supply chain… (cont.)
Confidential Hovione © 2020May 2020 46
• https://en.wikipedia.org/wiki/Timeline_of_the_2019%E2%80%9320_Wuhan_coronavirus_outbreak
• https://www.seattletimes.com/seattle-news/health/coronavirus-timeline-how-the-outbreak-unfolded/
• https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6
• https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
• https://www.pharmaceutical-technology.com/news/coronavirus-a-timeline-of-how-the-deadly-outbreak-evolved/
• https://www.cphi-online.com/updated-covid19-pharma-tracker-news082415.html
• https://www.dgs.pt/em-destaque.aspx
Sources